21:05 , Apr 26, 2019 |  BioCentury  |  Product Development

Cytokinetics’ muscle gambit nears POC for next-gen therapies

Cytokinetics is banking that its nearly 15 years of muscle biology research will pay dividends with its next-generation therapies for cardiovascular and neuromuscular disorders. The next signal will come in early May when the biotech...
01:45 , Nov 17, 2018 |  BioCentury  |  Product Development

MyoKardia’s myosin mechanism deconvolution

With preclinical proof of concept that its lead candidate mavacamten acts via two distinct mechanisms to treat cardiomyopathy, MyoKardia Inc. is ready to accelerate a pipeline of preclinical programs that exploit the mechanisms separately for...
18:09 , Oct 12, 2018 |  BC Week In Review  |  Clinical News

Cytokinetics' reldesemtiv misses COPD, frailty endpoints

Cytokinetics Inc. (NASDAQ:CYTK) and Astellas Pharma Inc. (Tokyo:4503) said reldesemtiv (CK-2127107) missed the primary and secondary endpoints in a Phase II trial to treat chronic obstructive pulmonary disease. The partners also said an interim analysis...
19:59 , Jul 13, 2018 |  BC Week In Review  |  Clinical News

Cytokinetics' SMA candidate improves time to muscle fatigue in Phase II

Cytokinetics Inc. (NASDAQ:CYTK) reported data from ambulatory patients with spinal muscular atrophy (SMA) in a Phase II trial showing that reldesemtiv led to dose-dependent increases in time to muscle fatigue from baseline to week eight...
18:20 , Jan 12, 2018 |  BC Week In Review  |  Clinical News

Cytokinetics reports additional Phase III data for suspended ALS candidate

Cytokinetics Inc. (NASDAQ:CYTK) reported additional data from the Phase III VITALITY-ALS trial in 744 patients with amyotrophic lateral sclerosis (ALS) showing that tirasemtiv reduced mean percent predicted slow vital capacity (SVC) from baseline to week...
00:02 , Dec 1, 2017 |  BC Week In Review  |  Clinical News

Cytokinetics suspends development of ALS candidate on Phase III miss

Cytokinetics Inc. (NASDAQ:CYTK) said it will suspend development of tirasemtiv after the candidate missed the primary and secondary endpoints in the Phase III VITALITY-ALS trial to treat amyotrophic lateral sclerosis (ALS). On the double-blind, international...
18:35 , Nov 21, 2017 |  BC Extra  |  Clinical News

Cytokinetics falls on Phase III ALS readout for tirasemtiv

Cytokinetics Inc. (NASDAQ:CYTK) fell $2.85 (26%) to $8.25 on Tuesday after the company said it will suspend development of tirasemtiv as the candidate missed the primary and secondary endpoints in the Phase III VITALITY-ALS trial...
21:26 , Sep 29, 2017 |  BC Week In Review  |  Clinical News

Cytokinetics starts Phase II trial of CK-2127107 to treat ALS

Cytokinetics Inc. (NASDAQ:CYTK) began the Phase II FORTITUDE-ALS trial of CK-2127107 (CK-107) to treat amyotrophic lateral sclerosis (ALS). The double-blind, placebo-controlled trial will enroll about 450 patients to receive 150, 300, or 450 mg oral...
18:48 , Jul 21, 2017 |  BC Week In Review  |  Clinical News

Cytokinetics starts Phase Ib trial of CK-2127107 to treat eldery adults with limited mobility

Cytokinetics Inc. (NASDAQ:CYTK) and Astellas Pharma Inc. (Tokyo:4503) began a Phase 1b trial of CK-2127107 to treat elderly patients with limited mobility. The double-blind, crossover trial will enroll at least 60 patients to receive placebo...
21:41 , Jun 28, 2017 |  BC Extra  |  Company News

Scholar Rock developing lead candidate for SMA

Scholar Rock LLC (Cambridge, Mass.) said it will develop its lead candidate SRK-015 to treat spinal muscular atrophy. CEO Nagesh Mahanthappa told BioCentury the company plans to submit an IND and begin Phase I testing...